PMID- 27044356
OWN - NLM
STAT- MEDLINE
DCOM- 20161226
LR  - 20181113
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 33
IP  - 5
DP  - 2016 May
TI  - FGFR3 promotes angiogenesis-dependent metastasis of hepatocellular carcinoma via 
      facilitating MCP-1-mediated vascular formation.
PG  - 46
LID - 10.1007/s12032-016-0761-9 [doi]
AB  - The biological role of fibroblast growth factor receptor 3 (FGFR3) in tumor 
      angiogenesis of hepatocellular carcinoma (HCC) has not been discussed before. Our 
      previous work had indicated FGFR3 was overexpressed in HCC, and silencing FGFR3 
      in Hu7 cells could regulate tumorigenesis via down-regulating the phosphorylation 
      level of key members of classic signaling pathways including ERK and AKT. In the 
      present work, we explored the role of FGFR3 in angiogenesis-dependent metastasis 
      by using SMMC-7721 and QGY-7703 stable cell lines. Our results indicated FGFR3 
      could regulate in vitro cell migration ability and in vivo lung metastasis 
      ability of HCC, which was in accordance with increased angiogenesis ability in 
      vitro and in vivo. Using the supernatant from SMMC-7721/FGFR3 cells, we conducted 
      a human angiogenesis protein microarray including 43 angiogenesis factors and 
      found that FGFR3 modulated angiogenesis and metastasis of HCC mainly by promoting 
      the protein level of monocyte chemotactic protein 1 (MCP-1). Silencing FGFR3 by 
      short hairpin RNA (shRNA) could reduce MCP-1 level in lysates and supernatant of 
      QGY-7703 cells and SMMC-7721 cells. Silencing MCP-1 in QGY-7703 or SMMC-7721 
      cells could induce similar phenotypes compared with silencing FGFR3. Our results 
      suggested FGFR3 promoted metastasis potential of HCC, at least partially if not 
      all, via facilitating MCP-1-mediated angiogenesis, in addition to previously 
      found cell growth and metastasis. MCP-1, a key medium between HCC cells and 
      HUVECs, might be a novel anti-vascular target in HCC.
FAU - Liu, Xinyu
AU  - Liu X
AD  - Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, 
      Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Rd, 
      Shanghai, 200025, China.
FAU - Jing, Xiaoqian
AU  - Jing X
AD  - Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, 
      Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Rd, 
      Shanghai, 200025, China.
FAU - Cheng, Xi
AU  - Cheng X
AD  - Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, 
      Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Rd, 
      Shanghai, 200025, China.
FAU - Ma, Ding
AU  - Ma D
AD  - Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, 
      Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Rd, 
      Shanghai, 200025, China.
FAU - Jin, Zhijian
AU  - Jin Z
AD  - Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, 
      Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Rd, 
      Shanghai, 200025, China.
FAU - Yang, Weiping
AU  - Yang W
AD  - Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, 
      Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Rd, 
      Shanghai, 200025, China. drqwh2003@yahoo.com.
FAU - Qiu, Weihua
AU  - Qiu W
AD  - Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, 
      Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Rd, 
      Shanghai, 200025, China. drqwh2003@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160404
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - EC 2.7.10.1 (FGFR3 protein, human)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3)
SB  - IM
MH  - Animals
MH  - Carcinoma, Hepatocellular/blood supply/*pathology
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Chemokine CCL2/genetics/*metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - Human Umbilical Vein Endothelial Cells
MH  - Humans
MH  - Liver Neoplasms/blood supply/*pathology
MH  - Male
MH  - Mice, Nude
MH  - Neovascularization, Pathologic/*genetics
MH  - Receptor, Fibroblast Growth Factor, Type 3/*genetics/metabolism
MH  - Xenograft Model Antitumor Assays
OTO - NOTNLM
OT  - Angiogenesis
OT  - FGFR3
OT  - Hepatocellular carcinoma
OT  - MCP-1
EDAT- 2016/04/06 06:00
MHDA- 2016/12/27 06:00
CRDT- 2016/04/06 06:00
PHST- 2015/12/13 00:00 [received]
PHST- 2016/03/30 00:00 [accepted]
PHST- 2016/04/06 06:00 [entrez]
PHST- 2016/04/06 06:00 [pubmed]
PHST- 2016/12/27 06:00 [medline]
AID - 10.1007/s12032-016-0761-9 [pii]
AID - 10.1007/s12032-016-0761-9 [doi]
PST - ppublish
SO  - Med Oncol. 2016 May;33(5):46. doi: 10.1007/s12032-016-0761-9. Epub 2016 Apr 4.